370 The Polyclonal Lymphoid Diseases PART VII DEFINITION Infectious mononucleosis is dened as any blood lymphocytosis induced in response to an infectious agent. Usually greater than 50 percent of the circulating white cells are lymphocytes, more than 10 percent of which have the morphology of reactive lymphocytes (see Fig. 531). Table 531 lists the etiologic agents that produce mononucleosis. Pharyngeal form: Sore throat preceded by 1 to 2 weeks of lethargy. Epstein-Barr virus (EBV) generally is the cause. Glandular form without pharyngitis: Lymph node enlargement. Usually caused by agents other than EBV, e.g., Toxoplasma gondii. Typhoidal form: Lethargy with fever or diarrhea without pharyngitis, usually as a conse- quence of cytomegalovirus (CMV). A B C D FIGURE 531 AD. Blood lms from patients with EBV-induced mononucleosis. These reactive lymphocytes exhibit the characteristic changes seen in patients with infectious mononucleosis: large lymphocytes with abundant cytoplasm. The cytoplasmic margin often spreads around (is in- dented by) neighboring red cells and the margin may take on a densely basophilic coloration. This type of reactive T lymphocyte may be seen a variety of diseases and is not specic changes but are characteristic. (Reproduced with permission from Lichtmans Atlas of Hematology, www.access- medicine.com.) (Source: Williams Hematology, 8th ed, Chap. 84, Fig. 841, p. 1202.) MCGH194-Ch53.indd 370 2/6/11 11:43:16 AM CHAPTER 53 371 The Mononucleosis Syndromes TABLE 532 COMPLICATIONS IN PATIENTS WITH EBV OR CMV MONONUCLEOSIS EBV CMV Hemolytic anemia Thrombocytopenia Aplastic anemia Splenic rupture Jaundice ( age 25 years) Guillain-Barr* Encephalitis* / Pneumonitis* / Myocarditis* B-cell lymphoma Agammaglobulinemia *Can occur without mononucleosis syndrome. , common; , infrequent; /, uncom- mon; , not observed. Source: Williams Hematology, 8th ed, Chap. 84, Table 842, p. 1200. TABLE 531 ETIOLOGIC AGENTS ASSOCIATED WITH MONONUCLEOSIS SYNDROME Epstein-Barr virus Hepatitis A Cytomegalovirus Adenovirus Human immunodeciency virus Toxoplasma gondii Human herpes virus-6 Bartonella henselae Metapneumovirus Brucella abortus Rubella Source: Williams Hematology, 8th ed, Chap. 84, Table 841, p. 1200. ETIOLOGY AND PATHOGENESIS Caused by two members of the herpes virus family: EBV or CMV. After the early phase of fever, which lasts for 3 to 7 days, laboratory abnormali- ties include a blood lymphocyte proportion greater than 50 percent, often with greater than 10 percent reactive lymphocytes. Table 532 lists other complications of EBV and CMV mononucleosis. FEATURES OF MONONUCLEOSIS CAUSED BY EACH ETIOLOGIC AGENT Table 533 list the signs and symptoms associated with EBV and CMV mono- nucleosis. Target cell for EBV mononucleosis is the B lymphocyte. Target cell for CMV mononucleosis is the macrophage. The mononucleosis for both is the increase in reactive blood T lymphocytes. Hepatosplenomegaly common for both EBV and CMV mononucleosis. Incubation period for EBV or CMV is 30 to 50 days. EBV MONONUCLEOSIS Virology and Pathogenesis DNA virus of the gammaherpsevirinae subfamily. Infects 90 percent of the world population. Peak incidence occurs in the age group from 12 to 25 years and during the sum- mer months. MCGH194-Ch53.indd 371 2/6/11 11:43:19 AM 372 The Polyclonal Lymphoid Diseases PART VII TABLE 533 SIGNS AND SYMPTOMS OF EBV AND CMV: EFFECT OF AGE (PERCENT OF PATIENTS) Percent of Subjects Signs and Symptoms EBV (Age 1435 Years) EBV (Age 4072 Years) CMV (Age 3070 Years) Fever 95 94 85 Pharyngitis 95 46 15 Lymphadenopathy 98 49 24 Hepatomegaly 23 42 N/A Splenomegaly 65 33 3 Jaundice 8 27 24 Source: Williams Hematology, 8th ed, Chap. 84, Table 843, p. 1200. B lymphocytes are the initial target of EBV during primary infection. Surface receptor for EBV is CD21 on B cells. Initial infection causes polyclonal or oligoclonal B-cell proliferation. Neoantigen(s) on EBV-infected B cells induces a cytotoxic T-cell response. Most circulating lymphocytes are reactive T cells. Cytotoxic T cells destroy most EBV-infected B cells leading to disease resolution. Following infection, the virus persists throughout life in a latent form. Epidemiology Transmission requires close mucocutaneous contact. In the developing world and in the lowest socioeconomic strata of the developed world, nearly everyone is subclinically infected by age 5 years and mononucleo- sis is rarely clinically apparent. In the upper socioeconomic strata of the developed world, persons avoid infec- tion in infancy; instead, they become exposed to the virus between the ages of 12 and 25 years by contact with a latently infected asymptomatic individual. Individuals who are raised in more protected environments or in single-child families may reach an age of 30 years or older before they are infected. Clinical Manifestations Vary by age: When young children acquire infection with EBV, they develop a typical childhood illness of respiratory tract infection (43%), otitis media (29%), pharyngitis (21%), gastroenteritis (7%), or typical mononucleosis (10%). Age group 12 to 25 years, the earliest manifestations of diseasefever and lassitudedevelop 30 to 45 days after patients become infected. Initial symptoms of pharyngitis, tonsillar enlargement, sometimes massive, and fever result from infection and proliferation of the B lymphocytes that are found in the pharyngeal of the Waldeyer ring of the lymph nodes. Liver function abnormalities, usually cholestatic, are frequently present. Maculopapular rash with EBV mononucleosis can be worsened by administra- tion of ampicillin or amoxicillin. Group A streptococcus infection may occur coincidentally, but does not affect the disease and its usual course. Penicillin or erythromycin indicated if group A streptococcus isolated from throat cultures of symptomatic patients. MCGH194-Ch53.indd 372 2/6/11 11:43:20 AM CHAPTER 53 373 The Mononucleosis Syndromes Complications caused by immune dysregulation or lymphocyte proliferation: Immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia. Splenic rupture. Acute airway obstruction resulting from exaggerated pharyngeal lymphade- nopathy. B-cell lymphoproliferative disorder/lymphoma in immunosuppressed patients. Disease abates with the occurrence of a T-cell-mediated counter-response to the virus-induced polyclonal B-cell proliferation and clinical improvement occurs within 24 to 48 hours in most cases. Laboratory Findings Table 535 lists the laboratory abnormalities for EBV and CMV mononucleosis. Antibody Responses Heterophile antibody is positive only with EBV. Autoantibodies: Cold agglutinins occur frequently with EBV infection. Antibody tests for EBV: Antibodies to EBV do not react with CMV or with the heterophile antigen. IgM and IgG antivirus capsid antigen (VCA) appear during acute illness (IgM persists for months, IgG for life). Early antigen (EA) specic antibodies appear slightly later than IgG anti- VCA, and persist for years. Antibodies to Epstein-Barr nuclear antigen (EBNA) do not develop until after the acute illness resolves and persist for life. A presumptive diagnosis of EBV infectious mononucleosis may be made if the patient has antibodies specic for VCA, but not for EBNA. Reactive Lymphocytes Expansion of cytotoxic T lymphocytes produces lymphocytosis. Reactive lymphocytes are larger than lymphocytes normally found in the blood (see Fig. 531). Reactive lymphocytes are a hematologic hallmark of infectious mononucleosis, but they are not always found and are not pathognomonic. Other Blood Test Abnormalities Liver function abnormalities are common, predominantly elevated serum alka- line phosphatase and -aminotransferase activity with no or only slight eleva- tion of bilirubin in most patients. Course and Prognosis Complications of EBV Mononucleosis Hematologic: Occur infrequently, but include severe immune thrombocytopenia with petechiae, immune hemolytic anemia, immune-mediated agranulocytosis, and aplastic anemia. Neurologic: Can occasionally develop encephalitis, acute disseminated encephalomyeli- tis (Alice in Wonderland (( syndrome), acute cerebellar ataxia, viral meningi- d tis, Guillain-Barr syndrome, transverse myelitis, and cranial nerve palsies. Other complications that may be associated are chronic fatigue, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and chronic progressive EBV infection, T or NK lymphoproliferation, lymphoma, and hemophagocytic syndrome. MCGH194-Ch53.indd 373 2/6/11 11:43:20 AM 374 The Polyclonal Lymphoid Diseases PART VII Other EBV-Associated Disease Processes Neoplastic Potential of the Virus Has been associated Burkitt lymphoma and other tumors (see Table 534). Detectable in neoplastic B cells (Reed-Sternberg cells) of approximately 35 per- cent of patients with Hodgkin lymphoma; etiologic role uncertain. Because of the severe consequences of EBV infection, several approaches to preventing or treating these disorders are under way including: Development of an EBV vaccine. Adoptive transfer of activated cytotoxic T cells. Development of peptides that inhibit viral replication. CMV MONONUCLEOSIS Second most common cause of infectious mononucleosis. Epidemiology Teenage mothers carrying CMV in their cervix transmit it to their newborn child, and transmission also occurs through breast milk. Transmission from contact with infected young children also plays a role. Sexual transmission. Clinical Manifestations See Table 532 and 534 for a list of complications and clinical ndings. The basic clinical disease is fever, often as high as 40 C (104 F), with a palpa- ble spleen and laboratory abnormalities. Commonly occurs in older individuals, often those older than 50 years. Reactive lymphocytosis is a result of T cells reacting against CMV-infected monocytes/macrophages (see Table 534). TABLE 534 SPECIAL PROBLEMS WITH EBV OR CMV Epstein-Barr Virus Cytomegalovirus Rare congenital infection Congenital infection Chronic progressive mononucleosis Posttransplant primary infection Hemophagocytic syndrome Graft-versus-host disease association X-linked B-cell lymphoma Transfusion-related infection Posttransplant lymphoproliferative disease Aspergillus and/or s Pneumocystis infection T or NK lymphoproliferative disease African Burkitt lymphoma Approximately 20% of Burkitt lymphoma in the United States Approximately 35% of Hodgkin lymphoma Nasopharyngeal carcinoma Approximately 5% of gastric carcinoma Leiomyoma and leiomyosarcoma in HIV or immunosuppressed patients Oral hairy leukoplakia Source: Williams Hematology, 8th ed, Chap. 84, Table 844, p. 1203. MCGH194-Ch53.indd 374 2/6/11 11:43:20 AM CHAPTER 53 375 The Mononucleosis Syndromes TABLE 536 CLINICAL FINDINGS IN PRIMARY HIV INFECTION Finding Frequency (%) Fever 79 Pharyngitis 48 Oral ulcers 29 Lymphadenopathy 44 Splenomegaly 5 Hepatomegaly 1 Reactive lymphocytes Uncommon Source: Williams Hematology, 8th ed, Chap. 84, Table 846, p. 1205. Laboratory Findings See Table 535. Polyclonal antibody and heterophile antibody responses do not occur, but spe- cic anti-CMV antibodies do develop. Because the incubation period ranges between 30 and 40 days, IgM and IgG antibodies to CMV usually are positive at presentation. Tests for CMV: Primary infection diagnosed by fourfold rise in anti-CMV antibody titer. Assay for CMV antigenemia more sensitive than anti-CMV antibody titer. Polymerase chain reaction (PCR) for detection of CMV DNA is most sensitive. Complications Hemolytic anemia and thrombocytopenia occur in primary CMV infection and are other factors that may lead the clinician initially to consider a diagnosis of lymphoma. Various neurologic complications can occur, but Guillain-Barr syndrome is the most frequent and is usually associated with CMV infection. PRIMARY HIV INFECTION Mononucleosis can occur soon after primary infection (see Chap. 52). See Table 536 for the clinical ndings. Mononucleosis symptoms are self-limited but may last for several weeks. TABLE 535 LABORATORY ABNORMALITIES IN MONONUCLEOSIS SYNDROME Frequency EBV CMV Heterophile antibody Lymphocytosis
Reactive lymphocytes
Abnormal liver function
Antinuclear factor
Cold agglutinins
Cryoglobulins
Decreased platelets
, Characteristic; , common; , occurs. Source: Williams Hematology, 8th ed, Chap. 84, Table 845, p. 1204. MCGH194-Ch53.indd 375 2/6/11 11:43:20 AM 376 The Polyclonal Lymphoid Diseases PART VII Leukopenia, thrombocytopenia, a relative increase in band neutrophils, and a small proportion of reactive lymphocytes usually can be identied on the blood. Lymphocytosis is uncommon. OTHER AGENTS LINKED TO MONONUCLEOSIS SYNDROME Herpes virus-6 Varicella zoster. Hepatitis A or B. Rubella. Adenovirus. T. gondii: Only nonviral agent commonly identied as causing a mononucleosis syndrome. Infection secondary to ingestion of cysts in raw meat or of oocysts in cat feces. There is no documented person-to-person transmission. Is usually asymptomatic or isolated lymphadenopathy without fever. Patients do not commonly have pharyngitis. DIFFERENTIAL DIAGNOSIS Acute pharyngitis can be caused by infection with -hemolytic streptococcus, adenovirus, Arcanobacterium haemolyticum. Fever, lymphocytosis, and splenomegaly may raise consideration of lymphoma. CMV infection can be associated with presence of antinuclear antibodies simi- lar to those of patients with new-onset systemic lupus erythematosus. Mononucleosis syndrome of toxoplasmosis can be distinguished from that caused by other infections by presence of high-titer antitoxoplasma antibodies. Patients with mononucleosis syndrome secondary to hepatitis virus infection generally have abnormal liver function tests. THERAPY AND COURSE Disease is usually self-limited. Acetaminophen and/or gargling with saline for fever and pharyngitis. Prednisone 40 to 60 mg/day for 7 to 10 days, then taper dose over 1 week for severe or life-threatening complications, such as: Imminent upper airway obstruction. Immune thrombocytopenia purpura. Immune hemolytic anemia. Central nervous system involvement. Acyclovir generally is ineffective in the treatment of infectious mononucleosis. Ganciclovir may be benecial for immunocompromised patients or in patients with severe, complicated primary EBV mononucleosis. Ganciclovir (5 mg/kg day for 14 days) is effective against CMV, but recommended only for patients with severe disease and/or who are immunocompromised. Antiretroviral therapy for primary HIV-1 infection can clear viremia and restore CD4 lymphocytes (see Chap. 52). Mononucleosis in Pregnancy Abortion may be considered for any pregnant woman who develops infectious mononucleosis as a result of primary infection with EBV, CMV, or toxoplasmo- sis, especially during the rst trimester. EBV mononucleosis during gestation can produce severe congenital anomalies, including microcephaly, hepatosplenomegaly, cataracts, mental retardation, or death. MCGH194-Ch53.indd 376 2/6/11 11:43:21 AM CHAPTER 53 377 The Mononucleosis Syndromes About half of the infants born to mothers who develop primary CMV infection during pregnancy will have congenital infection. Of these, about one-quarter will be symptomatic and/or have congenital anomalies. Primary toxoplasmosis infection in rst trimester also can result in congenital abnormalities. Mothers with antitoxoplasmosis antibodies before pregnancy do not transmit the organism to the developing infant. HIV-1 can be transmitted to the infant during primary infection and should be treated with zidovudine alone or in combination with elective caesarean section to reduce the rate of maternal-infant HIV-1 transmission (see Chap. 52). For a more detailed discussion, see Robert F. Betts: Mononucleosis Syndromes. Chap. 84, p. 1199 in Williams Hematology, 8th ed. MCGH194-Ch53.indd 377 2/6/11 11:43:21 AM MCGH194-Ch53.indd 378 2/6/11 11:43:21 AM